@article{fcc3a2d563d74dcaa5b4b810ac23619c,
title = "Who is enrolling? The path to monitoring in type 1 diabetes trialnet{\textquoteright}s pathway to prevention",
abstract = "OBJECTIVE To better understand potential facilitators of individual engagement in type 1 diabetes natural history and prevention studies through analysis of enrollment data in the TrialNet Pathway to Prevention (PTP) study. RESEARCH DESIGN AND METHODS We used multivariable logistic regression models to examine continued engagement of eligible participants at two time points: 1) the return visit after screening to confirm an initial autoantibody-positive (Ab1) test result and 2) the initial oral glucose tolerance test (OGTT) for enrollment into the monitoring protocol. RESULTS Of 5,387 subjects who screened positive for a single autoantibody (Ab), 4,204 (78%) returned for confirmatory Ab testing. Younger age was associated with increased odds of returning for Ab confirmation (age <12 years vs. >18 years: odds ratio [OR] 2.12, P < 0.0001). Racial and ethnic minorities were less likely to return for confirmation, particularly nonwhite non-Hispanic (OR 0.50, P < 0.0001) and Hispanic (OR 0.69, P 5 0.0001) relative to non-Hispanic white subjects. Of 8,234 subjects, 5,442 (66%) were identified as eligible to be enrolled in PTP OGTT monitoring. Here, younger age and identification as multiple Ab1 were associated with increased odds of returning for OGTT monitoring (age <12 years vs. >18 years: OR 1.43, P < 0.0001; multiple Ab1: OR 1.36, P < 0.0001). Parents were less likely to enroll into monitoring than other relatives (OR 0.78, P 5 0.004). Site-specific factors, including site volume and U.S. site versus international site, were also associated with differences in rates of return for Ab1 confirmation and enrollment into monitoring. CONCLUSIONS These data confirm clear differences between successfully enrolled populations and those lost to follow-up, which can serve to identify strategies to increase ongoing participation.",
author = "Sims, {Emily K.} and Susan Geyer and Johnson, {Suzanne Bennett} and Ingrid Libman and Jacobsen, {Laura M.} and David Boulware and Rafkin, {Lisa E.} and Della Matheson and Atkinson, {Mark A.} and Henry Rodriguez and Maria Spall and Larsson, {Helena Elding} and Wherrett, {Diane K.} and Greenbaum, {Carla J.} and Jeffrey Krischer and DiMeglio, {Linda A.}",
note = "Funding Information: Acknowledgments. The authors acknowledge the support of the Type 1 Diabetes TrialNet Study Group, which identified study participants and provided samples and follow-up data for this study. Funding. E.K.S. receives funding support from National Institute of Diabetes and Digestive and Kidney Diseases K08-DK-103983 and the National Institutes of Health Loan Repayment Program. The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health through the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child HealthandHumanDevelopment,andtheNational Institute of Diabetes and Digestive and Kidney Diseases, through the cooperative agreements U01-DK-061010, U01-DK-061034, U01-DK-061042, U01-DK-061058, U01-DK-085453, U01-DK-085461, U01-DK-085465, U01-DK-085466, U01-DK-085476, U01-DK-085499, U01-DK-085504, U01-DK-085509, U01-DK-103153, U01-DK-103180, U01-DK-103266, U01-DK-103282, U01-DK-106984, U01-DK-106994, U01-DK-107013, U01-DK-107014, UC4-DK-097835, and UC4 DK-106993 and support from JDRF and the American Diabetes Association. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. E.K.S. planned analyses, interpreted data, and wrote the manuscript. S.G. planned analyses, evaluated and interpreted data, and edited the manuscript. S.B.J., I.L., L.M.J., D.B., L.E.R., D.M. , M.A.A., H.R., M.S., H.E.L., D.K.W., C.J.G., and J.K. interpreted data and edited the manuscript. L.A.D. planned analyses, interpreted data, and wrote and edited the manuscript. All authors read and approved the final version. E.K.S. and L.A.D. are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Funding Information: E.K.S. receives funding support from National Institute of Diabetes and Digestive and Kidney Diseases K08-DK-103983 and the National Institutes of Health Loan Repayment Program. The Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health through the National Institute of Allergy and Infectious Diseases, the EuniceKennedyShriverNationalInstituteofChild HealthandHumanDevelopment,andtheNational Institute of Diabetes and Digestive and Kidney Diseases, through the cooperative agreements U01-DK-061010, U01-DK-061034, U01-DK-061042, U01-DK-061058, U01-DK-085453, U01-DK-085461, U01-DK-085465, U01-DK-085466, U01-DK-085476, U01-DK-085499, U01-DK-085504, U01-DK-085509, U01-DK-103153, U01-DK-103180, U01-DK-103266, U01-DK-103282, U01-DK-106984, U01-DK-106994, U01-DK-107013, U01-DK-107014, UC4-DK-097835, and UC4 DK-106993 and support from JDRF and the American Diabetes Association. Publisher Copyright: {\textcopyright} 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.",
year = "2019",
month = dec,
day = "1",
doi = "10.2337/dc19-0593",
language = "English (US)",
volume = "42",
pages = "2228--2236",
journal = "Diabetes care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
number = "12",
}